Clinical Trials Logo
  1. Home
  2. Malignant Neoplasm of Breast
  3. NCT04654208
  4. Details
NCT04654208 Clinical Trial

Swedish Ibrance Registries Insights (SIRI)

Malignant Neoplasm of Breast Clinical Trial

— SIRI  

Official title:
Palbociclib Treatment Patterns in Swedish Patients With Metastatic Breast Cancer - Swedish Ibrance Registries Insights (SIRI)

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT04654208
Other study ID # A5481158
Secondary ID SIRI
Status Recruiting
Phase
First received
Last updated
Start date December 15, 2020
Est. completion date August 31, 2024

Study information
Verified date June 2024
Source Pfizer
Contact Pfizer CT.gov Call Center
Phone 1-800-718-1021
Email ClinicalTrials.gov_Inquiries@pfizer.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The main objectives of this study are to describe patient characteristics, treatment patterns and clinical outcomes of patients receiving palbociclib in Swedish clinical practice.

Recruitment information / eligibility
Status Recruiting
Enrollment 1500
Est. completion date August 31, 2024
Est. primary completion date August 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria: Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study: 1. One or more (=1) filled prescription of palbociclib (ATC code: L01XE33) 2. Age =18 years at index date Exclusion Criteria: There are no exclusion criteria

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• palbociclib
patients on palbociclib combination treatment

Locations
Country Name City State
Sweden Pfizer AB Sollentuna

Sponsors (1)
Lead Sponsor Collaborator
Pfizer

Country where clinical trial is conducted

Sweden, 

Outcome
Type Measure Description Time frame Safety issue
Primary Proportion of patients on treatment Proportion of patients who have not discontinued treatment will be assessed at various timepoints (Time Frame: treatment start date through end of study [assessed up to 48 months]) 01 January 2017 until 30 September 2020
Secondary Proportion of patients alive Proportion of patients alive on palbociclib combination treatment at different points in time (Time Frame: treatment start date through end of study [assessed up to 48 months]) 01 January 2017 until 30 September 2020
Secondary Describe the demographic and clinical characteristics of the patient population receiving palbociclib combination treatment 01 January 2017 until 30 September 2020
See also
  Status Clinical Trial Phase
Completed NCT02378337 - Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced Radiation Dose and Improved Image Quality N/A
Completed NCT01953003 - Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Phase 3
Not yet recruiting NCT01395706 - ICG Fluorescence Technique for the Detection of Sentinel Lymph Nodes Phase 2
Enrolling by invitation NCT05486520 - Low-field MRI for Breast Cancer Screening N/A
Completed NCT05159778 - Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA) Phase 2
Active, not recruiting NCT03379428 - Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer Phase 1/Phase 2
Completed NCT02891681 - Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Treatment N/A
Withdrawn NCT03261323 - Breast Reconstruction Following Breast Cancer in Very High Risk Patients N/A
Recruiting NCT04669873 - Accelerated Partial Breast Irradiation Versus Standard or Hypofractionated Whole-Breast Irradiation, in Early Breast Cancer, After Breast-conserving Surgery N/A
Completed NCT02408393 - MIRs03: Paravertebral Block With Ropivacaine Before Breast Cancer Surgery Phase 3
Completed NCT03289819 - Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC Phase 2
Completed NCT02495363 - Analgesic Effects of Ultrasound Guided PEC Blocks on Analgesic Opioid Consumption of Cancer Surgery Patients
Completed NCT03159195 - Ibrance Real World Insights
Completed NCT03425656 - Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer Phase 3
Active, not recruiting NCT05033756 - Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO Phase 2
Not yet recruiting NCT01641003 - Isolation and Characterization of Cancer Stem Cells Using iFP Technique N/A
Active, not recruiting NCT05364450 - Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors N/A
Active, not recruiting NCT03435952 - Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT Phase 1
Active, not recruiting NCT02204098 - Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy Phase 1
Not yet recruiting NCT06251544 - TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer Phase 1

External Links